4 Biotechs in the Race for Covid-19 Cure

NASDAQ: REGN | Regeneron Pharmaceuticals Inc. News, Ratings, and Charts

REGN – The race for a vaccine or cure to the Coronavirus has several top biotech names in the spotlight. Here are the 4 that investors should concentrate on now: REGN, BIIB, INO and NVAX. Read on for more…

The biotech sector has been on fire thanks to speculation about a potential coronavirus vaccine.  Take a close look at the sector’s POWR Ratings and you will find many of these stocks are rated quite highly.  Part of the sector’s rise is undoubtedly attributed to the work toward developing a coronavirus vaccine yet biotech has also become a safe haven of sorts where worried investors park their money during uncertain times.

It appears as though investors’ new mantra is “When in doubt, opt for tech.”  After all, biotech and tech as a whole has infinite potential while most other spaces have inherent limitations.  REGN, BIIB, INO and NVAX are worth paying particularly close attention to in the biotech sector.

Regeneron Pharmaceuticals (REGN)

Now that the coronavirus is washing across the globe, biotech stocks appear to be some of the best investments.  REGN shines particularly bright with As across the POWR Ratings board.  The POWR Ratings rank REGN third of 336 stocks in the biotech sector.

Though REGN is currently priced at a lofty $548, the upper end of the analysts’ price target is $657.  REGN scientists are hard at work developing a vaccine candidate for COVID-19.  However, a potential coronavirus vaccine is only one piece of this company’s business pie.  REGN’s eczema treatment, dubbed Dupixent, has been quite the success.  REGN also develops cancer immunotherapy and arthritis drugs.

If REGN’s clinical study of its coronavirus treatment (REGN-COV2) goes well this June, the stock is sure to take off.

Biogen (BIIB)

Novel therapies are necessary for treating the seemingly endless number of medical maladies including the coronavirus.  BIIB has partnered with Vir Biotechnology to create and manufacture a potential treatment for the virus.

Though Vir is a fairly small biotech firm, it can lean on BIIB for the production of the drug candidate.  If even the slightest bit of good news comes out of either camp, BIIB will pop. BIIB has the endorsement of none other than Warren Buffet so it is sure to receive considerable attention in the quarters to come.

Aside from progress on the COVID-19 front, BIIB is also making headway in therapy for Alzheimer’s disease with the anticipation that its Aducanumab treatment will be approved for use in the near future.

If you are skittish about this stock, look no further than the POWR Ratings.  BIIB is rated as a B (Buy) with an A Trade Grade, an A Peer Grade and an A Industry Rank grade.  Take a chance by rolling with Buffet on BIIB and you stand a good chance of winning.

Inovio Pharmaceuticals (INO)

Have you ever heard of electroporation?  If you are like most people, you struggle to pronounce this word, let alone understand it.  Electroporation is INO’s specialty.  This technology is the use of short pulses of electricity to boost cells’ uptake of helpful biopharmaceuticals.

INO’s stock was priced at $3 this time last year, soared to $14 this past March and now trades at $16.05.  The recent spike is the result of hype surrounding INO’s potential treatment for coronavirus.  The company recently finalized enrollment in an initial trial of its coronavirus vaccine that has shown promise in animal studies.  We will get word of the company’s phase 1 trial outcome in late June.

INO’s spin on a potential COVID-19 treatment modality is quite unique, relying on the use of DNA plasmids as opposed to injecting a weakened form of the virus into the body.  The POWR Ratings are quite bullish for INO.  The stock has As and Bs across the board but for a C Buy and Hold Grade.

Novavax (NVAX)

The rapid development of an effective and affordable vaccine is the name of the game now that the world has been quarantined amidst the pandemic.  NVAX specializes in value-added, differentiated vaccines for infectious diseases.

The POWR Ratings have NVAX ranked 33 of 336 stocks in the Biotech space.  NVAX has an A in every POWR Rating component but for the Buy and Hold component in which it has grades out as a B.

Aside from NVAX’s coronavirus vaccine candidate, the company is also making headway in a regulatory filing for a flu vaccine dubbed NanoFlu.  If either vaccine makes it to the market, NVAX will likely hit new heights.

Want More Great Investing Ideas?

9 “BUY THE DIP” Growth Stocks for 2020

Beware 3,000 on S&P?

7 “Safe-Haven” Dividend Stocks for Turbulent Times

 


REGN shares were unchanged in premarket trading Thursday. Year-to-date, REGN has gained 53.64%, versus a -7.20% rise in the benchmark S&P 500 index during the same period.


About the Author: Patrick Ryan


Patrick Ryan has more than a dozen years of investing experience with a focus on information technology, consumer and entertainment sectors. In addition to working for StockNews, Patrick has also written for Wealth Authority and Fallon Wealth Management. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
REGNGet RatingGet RatingGet Rating
Get RatingGet RatingGet Rating
INOGet RatingGet RatingGet Rating
NVAXGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Christmas in July for Stock Investors!

Yes, the S&P 500 (SPY) made new highs again on Tuesday. But really it is the 6X gain for the Russell 2000 small cap index Tuesday...and 12% gain this past week that is grabbing everyone’s attention. Let’s discuss why this is happening...if it will continue...and my 12 favorite stocks to rally in the weeks ahead. Read on for more...

3 Promising Tech Stocks Under $40 for Long-Term Investment

The increasing demand for technology services worldwide fuels the tech industry. Amid this backdrop, it could be wise to buy under $40 tech stocks, such as HP Inc. (HPQ), Box, Inc. (BOX), and Teradata Corp (TDC), for long-term investment. Continue reading…

3 MedTech Stocks to Add to Your Portfolio in July

The MedTech sector’s promising future is driven by technological advances, unceasing demand for medical treatments due to an aging population, and increasing global incidence of diseases. To that end, strong MedTech stocks such as Tactile Systems Technology (TCMD), Electromed (ELMD), and Embecta (EMBC) could be wise portfolio additions in July. Read more...

3 Bank Stocks Benefiting From High Interest Rates

Amid global economic uncertainties, major U.S. banks like JPMorgan (JPM), Wells Fargo & Company (WFC), and PNC Financial Services (PNC) have defied expectations with strong revenue and earnings reports for the second quarter. Considering their robust performance, investing in these stocks could offer stable returns to your portfolio. Read more…

Investor Alert: Load Up on Small Cap Stocks!

Large caps time in the sun is now over and thus no shock that the S&P 500 (SPY) pulled back from recent highs. It is time for small caps to shine which was clear in their nearly 4% gain Thursday even as the Magnificent 7 was bathed in red. Why is this happening? What comes next? And what are the best stocks to own now? The answers to all that and more are shared in the commentary below...

Read More Stories

More Regeneron Pharmaceuticals Inc. (REGN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All REGN News